Taken together, these results confirmed that PD-1/PD-L1 and IGF2BP2 expression is increased in hypopharyngeal cancer, and may serve as a therapeutic target for management of hypopharyngeal cancer. The gene discussed is IGF2BP2; the disease is hypopharynx cancer.